FDA Approval Sought for Frontline Cabozantinib in RCC

August 16, 2017 – A supplemental new drug application (sNDA) has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor. The sNDA is based on the phase II CABOSUN trial, in which cabozantinib reduced the risk of progression or death by 34% versus sunitinib as a first-line treatment for patients with metastatic RCC … (leggi tutto)